Table 1.
Blinatumomab for B cell precursor acute lymphoblastic leukemia
| Weight ≥ 45 kg (fixed dose) | Weight < 45 kg (BSA-based dose) | |
|---|---|---|
| CR1 or CR2 with *MRD-positive patients | ||
| Cycles 1–4 | ||
| Days 1–28 | 28 μg/day | 15 μg/m2/day (not to exceed 28 μg/day) |
| Days 29–42 | 14-day treatment-free interval | 14-day treatment-free interval |
| Relapsed or refractory patients | ||
| Induction cycle 1 | ||
| Days 1–7 | 9 μg/day | 5 μg/m2/day (not to exceed 9 μg/day) |
| Days 8–28 | 28 μg/day | 15 μg/m2/day (not to exceed 28 μg/day) |
| Days 29–42 | 14-day treatment-free interval | 14-day treatment-free interval |
| Induction cycle 2 | ||
| Days 1–28 | 28 μg/day | 15 μg/m2/day (not to exceed 28 μg/day) |
| Days 29–42 | 14-day treatment-free interval | 14-day treatment-free interval |
| Consolidation cycles 3–5 | ||
| Days 1–28 | 28 μg/day | 15 μg/m2/day (not to exceed 28 μg/day) |
| Days 29–42 | 14-day treatment-free interval | 14-day treatment-free interval |
| Continued therapy cycles 6–9 | ||
| Days 1–28 | 28 μg/day | 15 μg/m2/day (not to exceed 28 μg/day) |
| Days 29–84 | 56-day treatment-free interval | 56-day treatment-free interval |
CR complete remission, MRD minimal residual disease
*MRD is positive when blasts are ≥ 0.1% by flow cytometry in the bone marrow